AstraZeneca snaps up Amolyt Pharma for over $1 billion

There has been talk that perhaps dealmaking in the biopharmaceutical industry was waning following the the string of deal announcements in December 2023.

However, AstraZeneca has just put paid to that theory by announcing another takeover deal. This time the FTSE 100-listed company has agreed to purchase Amolyt Pharma, a France-based company focused on developing novel treatments for rare endocrine diseases...


Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Thursday, 14 March 2024, 7:19 am

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation